Cleveland Clinic Cancer Advances

Ruth Keri, PhD, Associate Director for Basic Research at Case Comprehensive Cancer Center and Professor of Cancer Biology at Cleveland Clinic, returns to the Cancer Advances Podcast to share the latest advancements in targeting YES1 protein to treat triple-negative breast cancer (TNBC). Listen as Dr. Keri discusses how YES1 impacts chemotherapy resistance, tumor growth, and EGFR inhibition, uncovering promising therapeutic opportunities and the potential clinical trials to improve outcomes for patients facing this aggressive cancer.